Are you routinely using neoadjuvant cemiplimab for cutaneous squamous cell carcinoma of any site?

No

Cutaneous squamous cell carcinoma (CSCC) most often arises in sun-exposed areas such as the head and neck regions. While surgical excision in these areas may be technically feasible, they may also be associated with cosmetic disfigurement, impaired function, and inadequate oncologic control. Most CS...

Patients with such cancer are usually referred to surgeons or dermatologists first. Through recent multidisciplinary conferences, we are now slowly switching treatment to a systemic neoadjuvant approach, more specifically with cemiplimab.

Rationale for this study: I am quoting the introduction of the...

As mentioned before, we are selectively using 'neoadjuvant' cemiplimab. More commonly, patients start therapy for unresectable disease, have a deep response, and we occasionally consider consolidative surgery when they achieve maximal response. This same paradigm is used for cutaneous squamous cell ...